



(51) International Patent Classification:

A61K 38/15 (2006.01) A61P 31/04 (2006.01)
 A61K 31/015 (2006.01) C07C 13/271 (2006.01)
 A61K 31/05 (2006.01) C07C 13/32 (2006.01)
 A61K 31/352 (2006.01) C07C 39/19 (2006.01)
 A61K 36/185 (2006.01) C07C 39/23 (2006.01)
 A61M 31/00 (2006.01) C07D 311/58 (2006.01)
 A61P 1/02 (2006.01) C07K 7/08 (2006.01)

(21) International Application Number:

PCT/CA2020/050613

(22) International Filing Date:

06 May 2020 (06.05.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/843,687 06 May 2019 (06.05.2019) US

(71) Applicant: THE UNIVERSITY OF BRITISH COLUMBIA [CA/CA]; University-Industry Liaison Office, #103-6190 Agronomy Road, Vancouver, British Columbia V6T 1Z3 (CA).


(72) Inventors: THOMPSON, Charles J.; 2515 Cornwall Avenue, Vancouver, British Columbia V6K 1C1 (CA). PRYJMA, Mark C.; 9 Vale Crescent, Ajax, Ontario L1S 5A4 (CA). LAMBERT, Dana M.; 6467 Wellington Avenue, West Vancouver, British Columbia V7W 2H7 (CA). DOSANJH, Manisha; 6339 128th Street, Surrey, British Columbia V3X 1S9 (CA).

(74) Agent: KINGWELL, Brian et al.; Gowling WLG (Canada) LLP, 550 Burrard Street, Suite 2300, Bentall 5, Vancouver, British Columbia V6C 2B5 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,

(54) Title: ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS

Figure 1



(57) Abstract: Pharmaceutical formulations are provided that include at least two antibiotically active ingredients: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of α -humulene and/or β -caryophyllene; and a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibiotically active ingredients may be provided in relative amounts that amplify their individual activities, including amounts that are synergistically effective in an assay to inhibit growth and/or reproduction of an *Enterococcus faecium* or an *Enterococcus faecalis*. Therapies are provided that utilize these formulations as anti-microbials, and provide for the combined use of two or more of the antibiotically active compounds.

CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- *with international search report (Art. 21(3))*
- *in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE*

ANTIBIOTIC CANNABINOID-TERPENE FORMULATIONS

FIELD OF THE INVENTION

[0001] The invention is in the field of medicinal preparations comprising a mixture
5 of two or more organic antibiotically active ingredients, optionally including specific
phenolic cannabinoids in optional combination with specific sesquiterpenes in
optional combination with a lipopeptide antibiotic such as daptomycin. The
therapeutic use of cannabinoid and/or sesquiterpene formulations is also disclosed,
for synergistic treatment of enterococcal infections, including combined uses with
10 lipopeptide antibiotics such as daptomycin.

BACKGROUND OF THE INVENTION

[0002] *Enterococcus faecium* and *Enterococcus faecalis* are bacterial species
that asymptotically colonize the gastrointestinal (GI) tract in humans, but can also
15 be pathogenic in certain circumstances (in the relevant literature, *Enterococcus*
faecium was previously classified as *Streptococcus faecium*, see Schleifer &
Kilpperbalz, 1984). In particular, these organisms are known to be a leading cause
of dangerous infections in hospital patients being treated with antibiotics. During
overgrowth, enterococci can penetrate the walls of the GI tract, moving into the liver
20 or bloodstream where they can cause peritonitis, or systemic infections (bacteremia).
Enterococci have been reported to be the third leading cause of endocarditis, the
complication of blood infections that has the greatest risk of mortality (Murdoch et al.,
2009). The intestinal colonization by enterococci, particularly in hospital patients,
may facilitate continual person-to-person spread by environmental contamination
25 from fecal droplets, leading to opportunistic infection. Passive transmission of fecal
matter to the urinary tract in catheterized patients has reportedly made enterococci
the second most common cause of catheter associated urinary tract infections (UTIs)
which can result in kidney damage (Hidron et al., 2008). *E. faecalis* and *E. faecium*
are associated with oral infections causing marginal periodontitis, root canal
30 infections, primary endodontic infections, persistent/secondary infections, dental
caries, peri-implantitis, periradicular abscesses and oral mucosal lesions (Najafi et
al., 2019). *E. faecium* is also an important multidrug-resistant nosocomial pathogen

causing biofilm-mediated infections in patients with medical devices (Paganelli et al., 2013).

[0003] Therapy for enterococcal infections is made more difficult by the frequency of antibiotic resistance. Traditional treatments involve penicillin administered with a synergistic aminoglycoside. However, the emergence of resistance, particularly mediated by a mutation in a penicillin binding protein (pbp5) in *E. faecium*, has severely limited the utility of this traditional strategy (Galloway-Pena et al., 2009, Arias & Murray, 2012). To combat penicillin resistant strains, vancomycin became the treatment of choice. However, *Enterococcus spp.* have become increasingly vancomycin resistant (VRE), frequently due to the acquisition of VanA and VanB vancomycin resistance systems (Arthur & Courvalin, 1993). From a public health perspective, the spread of VRE as a nosocomial infection has been particularly problematic since it reportedly causes 1.8 fold higher mortality and results in an average of 5 days longer hospital stay according to a meta-analysis (Prematunge et al., 2016).

[0004] Currently there are two drugs indicated for VRE treatment, linezolid and daptomycin. However, although linezolid resistance has been reported to be rare, daptomycin resistance appears to emerge frequently de novo during daptomycin treatment (Arias et al., 2011); in such strains, linezolid becomes the only effective antibiotic available. Linezolid as sole available therapy is problematic due to a litany of negative side effects, such as hepatic toxicity, myelosuppression, and serotonin syndrome (if used with other serotonergic drugs). Given the limited options for treatment of enterococcal infections and the adverse effects associated with existing treatments, new treatments are urgently needed.

[0005] A very wide range of physiological activities have been ascribed to compounds derived from flowering plants in the genus *Cannabis*, particularly phytocannabinoid compounds (see Cunha et al., 1980; Morales et al., 2017; US Patent No 6,630,507). There are more than 80 cannabinoids found in cannabis plant extracts (Russo, 2011), including: cannabidiol (CBD), its acid form cannabidiolic acid (CBDA), cannabichromene (CBC), its acid form cannabichromic acid (CBCA), cannabigerol (CBG), its acidic form cannabigerolic acid (CBGA), tetrahydrocannabinol (THC), and its acidic form, tetrahydrocannabinolic acid (THCA). Studies have suggested that *Cannabis* extracts, or compounds derived from

the *Cannabis* plant, have a very wide range of, often ill defined, anti-microbial activities (Van Klingeren & Ten Ham, 1976; Abdelaziz, 1982; Appendino et al., 2011; Appendino et al., 2008; Eisohly et al., 1982; Eisohly et al., 1982; Appendino et al., 2008; Turner & Eisohly, 1981; Mechoulam & Gaoni, 1965; WO2012/012498; 5 WO2018/011813).

[0006] Terpenes are another molecular constituent of plants, including *Cannabis* plants, that have been attributed with a wide range of physiological activities. For example, the distinctive aroma and flavour that hops lends to beer reportedly comes in part from particular sesquiterpenes (including α -humulene and β -caryophyllene; 10 see Steenackers et al., 2015). The terpenes in *Cannabis* are reported to include well over 100 distinct compounds (André et al., 2016). It has been reported that aromatic terpenes may modulate the physiological effects of cannabinoids, particularly the psychoactive effects (Russo, 2011).

15 BRIEF DESCRIPTION OF THE DRAWINGS

[0007] **Figure 1** includes 12 line graphs, illustrating the effects of CBD, CBG or CBC on *E. faecium* viability. Enterococcus strains 33D3 (A-C), 69C6 (D-F), 58C9 (G-I) and 55A6 (J-L) were incubated with 0x, 1x (1 mg/L), 2x (2mg/L), or 4x (4mg/L) the MIC of CBD (A,D,G,J), CBG (B,E,H,K) or CBC (C,F,I,L). CFU's were determined at 20 2, 4, 6, 8, and 24h by serial dilution.

[0008] **Figure 2** includes 8 line graphs, illustrating the effects of daptomycin (Dap), and Dap in combination with CBD, CBG or CBC, on daptomycin resistant *E. faecium* VRE strains 58C9 and 55A6 (*E. faecium* clinical strain 55A6 is resistant to daptomycin with a daptomycin MIC=8mg/L). As illustrated, adding approximately $\frac{1}{2}$ 25 MIC of each cannabinoid facilitated killing by daptomycin at approximately $\frac{1}{4}$ - $\frac{1}{8}$ x the MIC of daptomycin.

[0009] **Figure 3** includes 4 line graphs, illustrating the effect of various concentrations of CBD, CBG and CBC on bactericidal activity of daptomycin. *E. faecium* strain 33D3 was incubated with (A) no cannabinoid, or $\frac{1}{2}$ x (0.5mg/L) MIC 30 of (B) CBD, (C) CBG) or (D) CBC with 1x (1mg/L), $\frac{1}{2}$ x (0.5mg/L), $\frac{1}{4}$ x (0.25mg/L) or $\frac{1}{8}$ x (0.125mg/L) MIC of daptomycin. Aliquots were removed at 2, 4, 6, 8 and 24h plated to monitor viability (CFU). Data points are the means from three replicates with standard deviations presented as error bars.

[0010] **Figure 4** includes two bar graphs, illustrating the effect of CBD, CBG and CBC on biofilms of *E. faecium* strain 33D3.

5 SUMMARY

[0011] One general aspect of the innovations disclosed herein includes formulations that include at least two antibiotically active ingredients, for example selected from: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG). The formulations may also include a
10 sesquiterpene that is one or both of α -humulene and/or β -caryophyllene. The formulations can also include a lipopeptide antibiotic that is daptomycin or an analogue thereof. The formulations may include the antibiotically active ingredients in synergistically effective relative amounts, for example where an effective amount of the formulation is synergistically effective in an assay to inhibit growth and/or
15 reproduction of an *Enterococcus faecium* or an *Enterococcus faecalis*.

[0012] Implementations may include one or more of the following features. The formulation where there are two antibiotically active ingredients, and the two antibiotically active ingredients are the cannabinoid and the sesquiterpene. The formulation where there are two antibiotically active ingredients, and the two
20 antibiotically active ingredients are the cannabinoid and the lipopeptide antibiotic. The formulation including the cannabinoid, the sesquiterpene and the lipopeptide antibiotic. The formulation where there are two antibiotically active ingredients, and the two antibiotically active ingredients are the sesquiterpene and the lipopeptide antibiotic. The formulation of any one where the cannabinoid is one of CBC, CBD or
25 CBG. The formulation of any one where the cannabinoid is two of CBC, CBD and CBG. The formulation of any one where the cannabinoid includes CBC, CBD and CBG. The formulation of any one where the sesquiterpene, if present, is one of α -humulene or β -caryophyllene. The formulation of any one where the sesquiterpene, if present, includes α -humulene and β -caryophyllene. The formulation of any one
30 where the lipopeptide antibiotic, if present, is daptomycin. The formulation of any one where the sesquiterpene, when present, is present in a relative amount that provides at least a 2 to 128 fold decrease in the minimum inhibitory concentration (MIC) of the cannabinoid in the assay. The formulation of any one where the cannabinoid, when present, is present in a relative amount that provides at least a 2 to 128 fold decrease

in the minimum inhibitory concentration (MIC) of the sesquiterpene in the assay. The formulation of any one where the sesquiterpene and/or the cannabinoid, when present, is present in a relative amount that provides at least a 2 to 128 fold decrease in the minimum inhibitory concentration (MIC) of the lipopeptide antibiotic in the assay. The formulation of any one where the molar ratio of the sesquiterpene to the cannabinoid, when present, is ≥ 50 . The formulation of any one further including a pharmaceutically acceptable excipient, and where the antibiotically active ingredients are dissolved, dispersed, mixed or suspended in the formulation. The formulation of any one where the cannabinoid, when present, is present at 0.1 - 100 mg/L. The formulation of any one where the sesquiterpene, when present, is present at 0.1 - 500 mg/L. The formulation of any one where the cannabinoid and/or sesquiterpene, when present, are derived from a plant extract. The formulation where the plant is a *Cannabis sativa* or *Cannabis indica* plant. The formulation of any one where the formulation does not include any alternative cannabinoids, terpenes or lipopeptide antibiotics. The formulation of any one where the formulation includes essentially of two or more of the cannabinoid, the terpene or the lipopeptide antibiotic. Use of the formulation of any one to formulate a medicament. The use according where the medicament is for use in treating an enterococcal infection in a subject in need thereof. The use according where the enterococcal infection is an *Enterococcus faecium* or an *Enterococcus faecalis* infection. The use according to any one where the enterococcal infection is an oral infection. The use according where the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary infection, dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion. The use according to any one where the enterococcal infection is an antibiotic resistant enterococcal infection. The use according where the antibiotic resistant enterococcal infection is a vancomycin and/or daptomycin resistant enterococcal infection. The use according to any one where the formulation is for use in an amount that delivers an effective dose of the cannabinoid, when present, of from 1 to 5,000 mg per day, and/or an effective dose of the sesquiterpene, when present, of from 1 to 10,000 mg per day. Use of the formulation of any one to treat an enterococcal infection in a subject in need thereof. The formulation of any one for use to treat an enterococcal infection in a subject in need thereof. The formulation where the enterococcal infection is an *Enterococcus*

faecium or an *Enterococcus faecalis* infection. The formulation where the enterococcal infection is an oral infection. The formulation where the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary infection, dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion. The formulation of any one where the enterococcal infection is an antibiotic resistant enterococcal infection. The formulation where the antibiotic resistant enterococcal infection is a vancomycin and/or daptomycin resistant enterococcal infection. The formulation of any one where the formulation is for use in an amount of that delivers an effective dose of the cannabinoid, when present, of from 1 to 5,000 mg per day, and/or an effective dose of the sesquiterpene, when present, of from 1 to 10,000 mg per day.

[0013] Alternative aspects of the disclosed innovations include methods of treating an enterococcal infection in a subject in need thereof, including administering to the subject an effective amount of the formulations disclosed herein. Implementations may include one or more of the following features. The method including two antibiotically active ingredients, where the two antibiotically active ingredients are the cannabinoid and the sesquiterpene, further including treating the subject with an effective amount of one or more antibiotics, optionally where the antibiotic is daptomycin. The method including administering the cannabinoid in an effective amount of 1-5,000 mg/day. The method of any one including administering the sesquiterpene in an effective amount of 1-10,000 mg/day. The method of any one where the subject is a mammal. The method where the mammal is a human.

[0014] Alternative aspects of the present innovations include methods of treating a microbial infection in a subject in need thereof, including administering to the subject, sequentially or in combination, an effective amount of at least two antibiotically active compounds selected from: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG). The method of treating also includes a sesquiterpene that is one or both of α -humulene and/or β -caryophyllene; and. The method of treating also includes a lipopeptide antibiotic that is daptomycin or an analogue thereof. The method of treating also includes where the antibiotically active compounds are administered in synergistically effective relative amounts effective to treat the microbial infection.

[0015] Implementations of the disclosed methods may include one or more of the following features. The method where the synergistically effective relative amounts are synergistically effective to inhibit growth and/or reproduction of an *Enterococcus faecium* or an *Enterococcus faecalis* in an assay. The method where the cannabinoid and the sesquiterpene are co-administered, or the sesquiterpene and the lipopeptide antibiotic are co-administered, or the cannabinoid and the lipopeptide antibiotic are co-administered, or the cannabinoid the sesquiterpene and the lipopeptide antibiotic are co-administered. The method where the cannabinoid and the sesquiterpene, or the sesquiterpene and the lipopeptide antibiotic, or the cannabinoid and the lipopeptide antibiotic, or the cannabinoid the sesquiterpene and the lipopeptide antibiotic, are administered sequentially, in any order. The method of any one further including further treating the subject with the lipopeptide antibiotic alone. The method of any one where the cannabinoid, if administered, is one of CBC, CBD or CBG. The method of any one where the cannabinoid, if administered, is two of CBC, CBD and CBG. The method of any one where the cannabinoid, if administered, includes CBC, CBD and CBG. The method of any one where the sesquiterpene, if administered, is one of α -humulene or β -caryophyllene. The method of any one where the sesquiterpene, if administered, includes α -humulene and β -caryophyllene. The method of any one where the lipopeptide antibiotic, if administered, is daptomycin. The method of any one where the sesquiterpene, if administered, is administered in a relative amount that provides at least a 2 to 128 fold decrease in the minimum inhibitory concentration (MIC) of the cannabinoid when administered. The method of any one where the cannabinoid, if administered, is administered in a relative amount that provides at least a 2 to 128 fold decrease in the minimum inhibitory concentration (MIC) of the sesquiterpene when administered. The method of any one where the sesquiterpene and/or the cannabinoid, when administered, is administered in a relative amount that provides at least a 2 to 128 fold decrease in the minimum inhibitory concentration (MIC) of the lipopeptide antibiotic when administered. The method of any one where the microbial infection is an enterococcal infection. The method where the enterococcal infection is an *Enterococcus faecium* or an *Enterococcus faecalis* infection. The method where the enterococcal infection is an oral infection. The method where the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary infection,

dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion. The method of any one where the microbial infection is an antibiotic resistant infection. The method where the antibiotic resistant infection is a vancomycin and/or daptomycin resistant microbial infection.

5 **[0016]** In an alternative aspect, methods are provided for treating a bacterial infection in a subject in need thereof, comprising administering to the subject an effective amount of: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); and, a lipopeptide antibiotic that is daptomycin or an analogue thereof; wherein the cannabinoid and the lipopeptide
10 antibiotic are administered in an antibiologically effective weight ratio of from 16:1 to 1:16; and, wherein: if the cannabinoid is CBD, then the lipopeptide antibiotic is administered in an effective amount that is less than 4 mg/kg; and/or, if the cannabinoid is CBD, then the bacterial infection comprises infection by an infectious organism having a daptomycin MIC of 4 µg/mL or greater; and/or, if the cannabinoid
15 is CBD, then the bacterial infection comprises infection by an infectious organism for which results from an assay of bacterial growth indicate that daptomycin produces an inhibitory and/or bactericidal effect at concentrations of less than 4 µg/mL when administered with CBD in an amount that is less than the MIC of CBD. The infection may for example include an infection by an *Enterococcus faecium* or an
20 *Enterococcus faecalis*. These treatments may further include administering to the subject an effective amount of a sesquiterpene that is one or both of α-humulene and/or β-caryophyllene.

[0017] In an alternative aspect, antibiotic formulations are provided that include: a cannabinoid that is one or more of cannabichromene (CBC) and/or cannabigerol
25 (CBG); and, a lipopeptide antibiotic that is daptomycin or an analogue thereof; wherein the cannabinoid and the lipopeptide antibiotic are present in an antibiologically effective weight ratio of from 16:1 to 1:16. The cannabinoid may for example be present in an amount that reduces the minimum inhibitory concentration (MIC) of the lipopeptide antibiotic in an antibiotic assay, such as an
30 Enterococcal assay that assesses the inhibition of growth and/or reproduction of an *Enterococcus faecium* or an *Enterococcus faecalis*. In select embodiments, the cannabinoid reduces the MIC of the lipopeptide antibiotic in the assay when the cannabinoid is present in an amount that is less than the MIC of the cannabinoid.

These formulations may further include a sesquiterpene, such as one or both of α -humulene and/or β -caryophyllene.

DETAILED DESCRIPTION OF THE INVENTION

5 [0018] In one aspect, pharmaceutical formulations are provided that include at least two antibioticly active ingredients, selected from: a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); a sesquiterpene that is one or both of α -humulene and/or β -caryophyllene; and, a lipopeptide antibiotic that is daptomycin or an analogue thereof. The antibioticly effective ingredients may be provided in synergistically effective relative amounts. For example, the cannabinoid and the sesquiterpene may be provided at concentrations that are only antibioticly active in synergistic combinations, such as $\leq 1 \mu\text{g/ml}$ cannabinoid and $\leq 32 \mu\text{g/ml}$ terpene. In synergistic combination, the inhibitory concentrations of the partners may for example decrease, for example by two or more fold, for example from 2-16 fold. Alternatively, the relative weight ratio of cannabinoid to sesquiterpene may for example be from about 1:5 to 1:50, or 1:8 to 1:32, or from 1:12 to 1:32. The relative concentration of the antibioticly active ingredients in the formulation may be arranged so that an effective amount of the formulation would be synergistically effective in an assay to inhibit growth and/or reproduction of an *Enterococcus faecium* or an *Enterococcus faecalis*. A formulation that provides this synergistic formulation may be used for treating enterococcal or other microbial infections, for example for treating infections of enterococcal species that are relatively closely related to a reference strain of *Enterococcus faecium* or *Enterococcus faecalis* (see Zhong et al., 2017). For example, enterococcal species amenable to treatment may be at least as closely related to the reference strain as are the most distantly related strains of *E. faecium* and *E. faecalis*. The microorganisms amenable to treatment may for example be resistant to antibiotics, for example VRE strains or strains resistant to daptomycin. *Enterococcus durans* is for example amenable to treatment, for example in the context of veterinary diseases. Other enterococcal species closely related to *E. faecium* or *E. faecalis* may for example include *E. mundtii*, *E. durans*, *E. hirae*, *E. ratti*, *E. villorum*, *E. thailandicus* and *E. phoeniculicola*, *E. termitis*, *E. quebecensis*, *E. moraviensis*, *E. caccae*, *E. haemoperoxidus* and *E. silesiacus*]

[0019] In select embodiments, synergies and/or potentiation effects are maximized using concentrations of antibiotically active components that are below the MICs for each component, for example just below the MICs. The components may accordingly be present in relative amounts that approximate the ratio of the
5 respective MICs for the components. For example, this may occur when the molar ratio terpene/cannabinoid is ≥ 50 (reflecting the MIC ratio of the components).

[0020] The molar ratio of cannabinoid to sesquiterpene may for example be between 1:100 and 50:1. For example, synergistic combinations may have a molar ratio of cannabinoid to sesquiterpene between 1:8 and 1:32. A pharmaceutically
10 acceptable excipient may optionally be included in the formulation, and the cannabinoid and sesquiterpene may be dissolved, dispersed, mixed or suspended in the formulation. One method of formulation may involve producing a sterile lyophilized powder, for example in a vial for reconstitution.

[0021] The cannabinoid and sesquiterpene may for example be obtained from a
15 plant extract, such as an extract of *Cannabis sativa* or *Cannabis indica*. Biosynthetic approaches to the production of cannabinoids and sesquiterpenes are also available, as are a variety of synthetic approaches (based for example on approaches used to synthesize THC/dronabinol, see US Patent No. 7,323,576 and Trost and Dogra, 2007). Alternative approaches involve expressing cannabinoid biosynthetic genes in
20 recombinant hosts, such as recombinant yeast (see Luo et al., 2019).

[0022] Derivatives or analogues of daptomycin may for example be used as lipopeptide antibiotics, as alternatives or in addition to use of daptomycin itself (see Nguyen et al., 2006; Baltz, 2006; and, Miao et al., 2006; Nguyen et al., 2010). In select embodiments, a daptomycin analogue is a lipopeptide antibiotic that has an
25 antibiotic activity that synergizes with one or more of the cannabinoids and/or sesquiterpenes in the formulations disclosed herein, for example in assay of antibiotic activity against enterococcal species. Daptomycin analogues or derivatives may for example differ from daptomycin by virtue of the substitution of one or more amino acids therein, such as by conservative substitutions, for example substitutions
30 of 1, 2, 3, 4 or 5 amino acids therein, for example substitutions with natural or non-natural amino acids. Daptomycin analogues may for example include cyclic lipodepsipeptide daptomycin, or derivatives thereof in which the fatty acid chain attached to the Trp¹ amino group is an *anteiso*-undecanoyl, *iso*-dodecanoyl or

anteiso-tridecanoyl group.

[0023] One or more additional compounds may be included, or specifically excluded, in alternative formulations, including for example: terpenes, terpenoids, sterols, triglycerides, alkanes, squalene, tocopherol, carotenoids, chlorophyll, flavonoid glycosides, or alkaloids.

[0024] Anti-microbial formulations may be used to prophylactically or therapeutically treat microbial infections, or otherwise inhibit microbial growth or multiplication. An antibiotic is an antimicrobial that is active against bacteria, and in this context includes naturally-occurring and synthetic substances that kill or inhibit the growth or multiplication of bacteria by any mechanism, including antiseptic or disinfectant modalities.

[0025] Subjects amenable to treatment include mammalian subjects, such as human patients, laboratory animals (e.g., primates, rats, mice), livestock (e.g., cows, sheep, goats, pigs, horses, fowl), or household pets (e.g., dogs, cats, rodents, birds), for example belonging to the taxonomic groups of primates, canines, felines, bovines, caprines, equines, ovines, porcines, rodents, Aves or lagomorphs. Human patients to be treated may for example be male or female, or at a specific stage of development: neonate, infant, juvenile, adolescent, adult and geriatric. Specific veterinary indications amenable to treatment may for example include enterococcal infections in poultry, for example treatment of *Enterococcus cecorum* infections in chickens.

[0026] In alternative embodiments, formulation may be administered in a dosage or dosage form that delivers and/or sustains synergistically effective amounts of the active ingredients.

[0027] The cannabinoid and/or sesquiterpene components of the formulation may for example be in the form of a plant extract, or be derived from a plant extract, or be obtained from a culture, such as a culture of a recombinant host, such as a recombinant yeast expressing the components. Humulene and β -caryophyllene are isomers, often found together in a variety of plants. In addition, a pharmaceutically acceptable excipient may be included, and the formulation may be provided in a titratable dosage form. In select embodiments, the cannabinoid components of the formulation may be obtained as an extract from a plant of the *Cannabis* genus, for example *Cannabis sativa* or *Cannabis indica*, or from a culture of recombinant yeast

hosts. A wide variety of methods may be used to prepare these plant extracts, including, but not limited to, supercritical or subcritical extraction with CO₂, extraction with hot gas, and extraction with solvents. Formulations may also specifically exclude additional terpenoids or terpenes, including plant-derived terpenoids or terpenes, such as astaxanthin or other sesquiterpenes, tetraterpenes, triterpenes, diterpenes or monoterpenes.

[0028] A titratable dosage may for example be adapted to allow a patient to take the medication in doses smaller than the unit dose, wherein a "unit dose" is defined as the maximum dose of medication that can be taken at any one time or within a specific dosage period. Titration of doses will allow different patients to incrementally increase the dose until they feel that the medication is efficacious, as not all patients will require the same dose to achieve the same benefits. A person with a larger build or faster metabolism may require larger doses to achieve the same effect as another with a smaller build or slower metabolism. Therefore, a titratable dosage has advantages over a standard dosage form.

[0029] In select embodiments, formulations may be adapted to be delivered in such a way as to target one or more of the following: sublingual, buccal, oral, rectal, nasal, parenteral and via the pulmonary system. Formulations may for example be in one or more of the following forms: gel, gel spray, tablet, liquid, capsule, by injection, or for vaporization.

[0030] Conventional pharmaceutical practice may be employed to provide suitable formulations or compositions to administer the formulations to subjects. Routes of administration may for example include, parenteral, intravenous, intradermal, subcutaneous, intramuscular, intracranial, intraorbital, ophthalmic, intraventricular, intracapsular, intraspinal, intrathecal, intracisternal, intraperitoneal, intranasal, inhalational, aerosol, topical, sublingual or oral administration. Therapeutic formulations may be in the form of liquid solutions or suspensions; for oral administration, formulations may be in the form of tablets or capsules; for intranasal formulations, in the form of powders, nasal drops, or aerosols; and for sublingual formulations, in the form of drops, aerosols or tablets.

[0031] Methods well known in the art for making formulations are found in, for example, "Remington: The Science and Practice of Pharmacy" (21st edition), ed. David Troy, 2006, Lippincott Williams & Wilkins. Formulations for parenteral

administration may, for example, contain excipients, sterile water, or saline, polyalkylene glycols such as polyethylene glycol, oils of vegetable origin, or hydrogenated naphthalenes. Biocompatible, biodegradable lactide polymer, lactide/glycolide copolymer, or polyoxyethylene-polyoxypropylene copolymers may
5 be used to control the release of the compounds. Other potentially useful parenteral delivery systems for include ethylene-vinyl acetate copolymer particles, osmotic pumps, implantable infusion systems, and liposomes. Formulations for inhalation may contain excipients, for example, lactose, or may be aqueous solutions containing, for example, polyoxyethylene-9-lauryl ether, glycocholate and
10 deoxycholate, or may be oily solutions for administration in the form of nasal drops, or as a gel.

[0032] Pharmaceutical compositions of the present invention may be in any form which allows for the composition to be administered to a patient. For example, the composition may be in the form of a solid, liquid or gas (aerosol). Pharmaceutical
15 composition of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a patient may take the form of one or more dosage units, where for example, a tablet, capsule or cachet may be a single dosage unit, and a container of the compound in aerosol form may hold a plurality of
20 dosage units.

[0033] Materials used in preparing the pharmaceutical compositions should be pharmaceutically pure and non-toxic in the amounts used. The inventive compositions may include one or more compounds (active ingredients) known for a particularly desirable effect. It will be evident to those of ordinary skill in the art that
25 the optimal dosage of the active ingredient(s) in the pharmaceutical composition will depend on a variety of factors. Relevant factors include, without limitation, the type of subject (e.g., human), the particular form of the active ingredient, the manner of administration and the composition employed.

[0034] In general, the pharmaceutical composition includes a formulation of the
30 present invention as described herein, in admixture with one or more carriers. The carrier(s) may be particulate, so that the compositions are, for example, in tablet or powder form. The carrier(s) may be liquid, with the compositions being, for example,

an oral syrup or injectable liquid. In addition, the carrier(s) may be gaseous, so as to provide an aerosol composition useful in, e.g., inhalatory administration.

[0035] When intended for oral administration, the composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.

[0036] As a solid formulation for oral administration, the composition may be formulated into a powder, granule, compressed tablet, pill, capsule, cachet, chewing gum, wafer, lozenges, or the like form. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following adjuvants may be present: binders such as syrups, acacia, sorbitol, polyvinylpyrrolidone, carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin, and mixtures thereof; excipients such as starch, lactose or dextrans, disintegrating agents such as alginic acid, sodium alginate, Primogel, corn starch and the like; lubricants such as magnesium stearate or Sterotex; fillers such as lactose, mannitols, starch, calcium phosphate, sorbitol, methylcellulose, and mixtures thereof; lubricants such as magnesium stearate, high molecular weight polymers such as polyethylene glycol, high molecular weight fatty acids such as stearic acid, silica, wetting agents such as sodium lauryl sulfate, glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin, a flavoring agent such as peppermint, methyl salicylate or orange flavoring, and a coloring agent. When the composition is in the form of a capsule, e.g., a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or a fatty oil.

[0037] The formulation may be in the form of a liquid, e.g., an elixir, syrup, solution, aqueous or oily emulsion or suspension, or even dry powders which may be reconstituted with water and/or other liquid media prior to use. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred compositions contain, in addition to the present compounds, one or more of a sweetening agent, thickening agent, preservative (e.g., alkyl p-hydroxybenzoate), dye/colorant and flavor enhancer (flavorant). In a composition intended to be administered by injection, one or more of a surfactant, preservative (e.g., alkyl p-hydroxybenzoate), wetting agent, dispersing agent, suspending agent (e.g., sorbitol, glucose, or other sugar syrups), buffer, stabilizer

and isotonic agent may be included. The emulsifying agent may be selected from lecithin or sorbitol monooleate.

[0038] The liquid pharmaceutical formulations of the invention, whether they be solutions, suspensions or other like form, may include one or more of the following
5 adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as
10 ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An
15 injectable pharmaceutical composition is preferably sterile.

[0039] The pharmaceutical formulation may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment, cream or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water
20 and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device.

[0040] The formulation may be intended for rectal administration, in the form, e.g.,
25 of a suppository which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol. Low-melting waxes are preferred for the preparation of a suppository, where mixtures of fatty acid glycerides and/or cocoa butter are suitable
30 waxes. The waxes may be melted, and the aminocyclohexyl ether compound is dispersed homogeneously therein by stirring. The molten homogeneous mixture is then poured into convenient sized molds, allowed to cool and thereby solidify.

[0041] The formulation may include various materials which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials which form the coating shell are typically inert, and may be selected from, for example, 5 sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule or cachet.

[0042] The pharmaceutical formulation may consist of gaseous dosage units, e.g., it may be in the form of an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized 10 packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system which dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a 15 kit.

[0043] Some biologically active compounds may be in the form of the free base or in the form of a pharmaceutically acceptable salt such as the hydrochloride, sulfate, phosphate, citrate, fumarate, methanesulfonate, acetate, tartrate, maleate, lactate, mandelate, salicylate, succinate and other salts known in the art. The 20 appropriate salt would be chosen to enhance bioavailability or stability of the compound for the appropriate mode of employment (e.g., oral or parenteral routes of administration).

[0044] The present invention also provides kits that contain a pharmaceutical formulation, together with instructions for the use of the formulation. Preferably, a 25 commercial package will contain one or more unit doses of the formulation. Formulations which are light and/or air sensitive may require special packaging and/or formulation. For example, packaging may be used which is opaque to light, and/or sealed from contact with ambient air, and/or formulated with suitable coatings or excipients.

30 **[0045]** The formulations of the invention can be provided alone or in combination with other compounds (for example, small molecules, nucleic acid molecules, peptides, or peptide analogues), in the presence of a carrier or any pharmaceutically or biologically acceptable carrier. As used herein "pharmaceutically acceptable

carrier” or “excipient” includes any and all solvents, dispersion media, coatings, antibacterial and antifungal agents, isotonic and absorption delaying agents, and the like that are physiologically compatible. The carrier can be suitable for any appropriate form of administration. Pharmaceutically acceptable carriers generally
5 include sterile aqueous solutions or dispersions and sterile powders. Supplementary active compounds can also be incorporated into the formulations.

[0046] An “effective amount” of a formulation according to the invention includes a therapeutically effective amount or a prophylactically effective amount. A “therapeutically effective amount” refers to an amount effective, at dosages and for
10 periods of time necessary, to achieve the desired therapeutic result. A therapeutically effective amount of a formulation may vary according to factors such as the disease state, age, sex, and weight of the individual, and the ability of the compound to elicit a desired response in the individual. Dosage regimens may be adjusted to provide the optimum therapeutic response. A therapeutically effective
15 amount may also be one in which any toxic or detrimental effects of the formulation or active compound are outweighed by the therapeutically beneficial effects. A “prophylactically effective amount” refers to an amount effective, at dosages and for periods of time necessary, to achieve the desired prophylactic result. Typically, a prophylactic dose is used in subjects prior to or at an earlier stage of disease, so that
20 a prophylactically effective amount may be less than a therapeutically effective amount. For any particular subject, the timing and dose of treatments may be adjusted over time (e.g., timing may be daily, every other day, weekly, monthly) according to the individual need and the professional judgment of the person administering or supervising the administration of the compositions.

[0047] With respect to effective amounts of antibiotic treatments, although the daptomycin susceptibility breakpoint for enterococci is considered to be 4 mg/L, ongoing debate exists as to whether this is appropriate given that approved doses are optimized only when MIC $\leq$ 1 mg/L. For example, a recent study found that when the MIC was 4 mg/L, the probability of attaining target pharmacokinetic parameters
30 in daptomycin-treated enterococcal bacteremia reached only 1.5 – 5.5% when 6 mg/kg doses were administered (Avery, Lindsay M et al. “Pharmacodynamic Analysis of Daptomycin-treated Enterococcal Bacteremia: It Is Time to Change the Breakpoint.” Clinical Infectious Diseases Vol. 68,10 (2019): 1650-1657).

[0048] In therapeutic applications, synergy between active ingredients occurs when an observed combined therapeutic effect is greater than the sum of therapeutic effects of individual active ingredients, or a new therapeutic effect is produced that the active ingredients could not produce alone. Accordingly, when components of a formulation are present in synergistically effective amounts, the formulation yields a therapeutic effect that is greater than would be achieved by the individual active ingredients administered alone at comparable dosages. In this context, the enhancement of therapeutic effect may take the form of increased efficacy or potency and/or decreased adverse effects. The synergistic effect may be mediated in whole or in part by the pharmacokinetics and/or pharmacodynamics of the active ingredients in a subject, so that the amount and proportion of the ingredients in the formulation may be synergistic *in vivo*. This *in vivo* synergy may be effected with a formulation that includes the active ingredients in amounts and proportions that are also synergistic in *in vitro* assays of efficacy. As used herein, the term “synergistically effective amounts” accordingly refers to amounts that are synergistic *in vivo* and/or *in vitro*. A numeric quantification of synergy is often expressed as a fractional inhibitory concentration index (FICI), which represents the sum of the fractional inhibitory concentrations (FICs) of each drug tested, where the FIC is determined for each drug by dividing the minimum inhibitory concentration (MIC, the lowest concentration of the drug which prevents visible growth of the bacterium in a standard *in vitro* assay – standard colorimetric assay based on resazurin) of each drug when used in combination by the MIC of each drug when used alone. In very general terms, a FICI lower or higher than 1 indicates positively correlated activity (at least additive or potentiation) or an absence of positive interactions, respectively. More definitively, synergy of two compounds may be conservatively defined as a FICI of ≤ 0.5 (see Odds, 2003; with additivity or potentiation corresponding to a FICI of >0.5 to ≤ 0.75 ; no interaction (indifference) corresponding to a FICI of >1 to ≤ 4 ; and antagonism corresponding to a FICI of $>>4$). Synergy of three compounds has been defined as a FICI of ≤ 1.0 . (Berenbaum, 1978; Yu et al., 1980). To estimate the optimal concentrations in triple combinations, the optimal concentrations of trans-caryophyllene and cannabinoid were utilized in combination with a series of daptomycin dilutions.

[0049] Although various embodiments of the invention are disclosed herein, many adaptations and modifications may be made within the scope of the invention in accordance with the common general knowledge of those skilled in this art. Such modifications include the substitution of known equivalents for any aspect of the invention in order to achieve the same result in substantially the same way. Numeric ranges are inclusive of the numbers defining the range. The word "comprising" is used herein as an open-ended term, substantially equivalent to the phrase "including, but not limited to", and the word "comprises" has a corresponding meaning. As used herein, the singular forms "a", "an" and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a thing" includes more than one such thing.

[0050] Citation of references herein is not an admission that such references are prior art to the present invention. Any priority document(s) and all publications, including but not limited to patents and patent applications, cited in this specification are incorporated herein by reference. All documents cited or referenced in herein cited documents, together with any manufacturer's instructions, descriptions, product specifications, and product sheets for any products mentioned herein or in any document incorporated by reference herein, are hereby incorporated herein by reference, and may be employed in the practice of the invention. More specifically, all referenced documents are incorporated by reference to the same extent as if each individual publication were specifically and individually indicated to be incorporated by reference herein and as though fully set forth herein. The invention includes all embodiments and variations substantially as hereinbefore described and with reference to the examples and drawings. In some embodiments, the invention excludes steps that involve medical or surgical treatment.

EXAMPLES

Example 1:

[0051] As illustrated in this Example, the non-psychotropic cannabinoids, cannabidiol, cannabigerol and cannabichromene (i.e., CBD, CBG, and CBC), have bacteriostatic (Tables 1, 2) and bactericidal (Figure 1) activities against *E. faecium* and *E. faecalis*, including strains that are sensitive or resistant to vancomycin and, in some cases, also resistant to daptomycin. At equal concentrations of CBD, CBG, or

CBC, the kinetics of *E. faecium* killing with CBG and CBC are faster than for CBD (Figure 1). It is further shown that cannabinoids can also increase the activity of daptomycin (MIC) by 8-128 fold (Table 3). In addition, we demonstrate that each cannabinoid has species specific activities against Gram positive (but not Gram negative) bacteria (Table 1).

[0052] As further illustrated in this Example, the non-psychotropic cannabinoids, cannabidiol, cannabigerol and cannabichromene (i.e., CBD, CBG, and CBC), trans-caryophyllene, and daptomycin act in synergy. Assays for interactions between all pairwise as well as triple combinations of cannabinoids (CBC, CBD, CBG), trans caryophyllene, and daptomycin are shown in Table 4. All pairwise combinations showed synergistic ($FICI \leq 0.5$) or potentiating ($FICI \geq 0.5, \leq 0.75$) interactions. However, while α -humulene (β -caryophyllene, data not shown) and trans caryophyllene had synergistic activities with CBC, CBD, or CBG (Table 4), other terpenes (α -pinene and R-(+) limonene) had no detectable activity either alone or in combination ($MIC > 32$ mg/L; data not shown). All triple combination were synergistic ($FICIs < 1.0$). Under these conditions, the MIC of daptomycin decreased 256-fold (from 8 to 0.03 μ g/ml in the presence of CBD and trans caryophyllene; Table 5) or >512 fold (from >16 to 0.03 in the presence of CBC and trans caryophyllene, Table 7D).

[0053] As illustrated in Tables 6 and 7, analyses of double and triple combinations against the drug resistant (daptomycin and vancomycin) strain VRE 55A6 showed that daptomycin/terpene/cannabinoid combinations are even more effective against this strain (compared to the vancomycin/daptomycin sensitive strain 33D3), increasing the MIC of daptomycin > 500 fold (effectively suppressing the daptomycin resistance phenotype).

[0054] The data presented in this Example was obtained as set out below.

MIC determination for all bacteria except *Mycobacterium* species:

[0055] Pre-cultures of bacteria growing in their corresponding liquid media (defined below) were diluted to an OD600 of 0.0025 and 100 μ l was added to 100 μ l of medium containing serial 2-fold dilutions of cannabinoid (cannabinoid stocks, in methanol or acetonitrile for acidic forms, were diluted in growth medium) in 96-well

plates. Plates were then incubated for 20-24 h at 37°C, and growth was recorded as OD600 in a Thermo Scientific™ Varioskan™ Flash Multimode Reader.

MIC determination for *Mycobacterium abscessus* ATCC 19977:

- 5 **[0056]** Pre-cultures growing in MHII medium with 0.05% tyloxapol were diluted to an OD600 of 0.005 in MHII medium, and 100 µl was added to 100 µl of MHII medium containing serial 2-fold dilutions of cannabinoid (cannabinoid stocks in methanol or acetonitrile for acidic forms were diluted in growth medium) in 96-well plates. Plates were then incubated for 48 h, followed by the addition of 30 µl the colorimetric reagent
10 resazurin in water (10 mg/100 ml). Plates were incubated for an additional 24 h, and growth was recorded as conversion of culture color from blue to pink.

MIC determination for *Mycobacterium tuberculosis* H37Rv:

- [0057]** Pre-cultures of *M. tuberculosis* growing in 7H9 medium plus 0.05%
15 tyloxapol, were grown to mid-log phase and diluted to OD600 0.0025 in the same medium without tyloxapol. 50 µL of diluted culture were used to inoculate wells in 96-well plates containing 50 µL of the same medium with serial 2-fold dilutions of cannabinoid (cannabinoid stocks in methanol or acetonitrile were diluted in growth medium). Plates were incubated for 5 days at 37°C, 5% CO₂, followed by the
20 addition of 10 µL PrestoBlue Cell Viability Reagent to each well. Plates were incubated for a further 24 h at 37°C, 5% CO₂ and then fluorescence (excitation 530 nm, emission 590 nm) was read on a Synergy HT plate reader.

Growth media used for various organisms:

- 25 *Enterococcus faecium*: all strains (**clinical isolates 33D3, 69C6, 58C9, and 55A6**), MHII (Mueller Hinton II)
Enterococcus faecalis: MHII (Mueller Hinton II)
Streptococcus pyogenes ATCC 51878: BHI (Brain Heart Infusion*)
Staphylococcus aureus MRSA USA 300: LB (Luria-Bertani)
30 *Staphylococcus epidermidis* ATCC 14990: NB (Nutrient Broth)
Staphylococcus epidermidis ATCC 12228: NB (Nutrient Broth)
Mycobacterium abscessus ATCC 19977: MHII (Mueller Hinton II)
Mycobacterium tuberculosis H37Rv: 7H9

Mycobacterium tuberculosis H37Rv: PB (Proskauer and Beck + glucose and sodium pyruvate)

Acinetobacter baumannii ATCC 19606: NB (Nutrient Broth)

Escherichia coli HB101: (LB (Luria-Bertani)

5 *Pseudomonas aeruginosa* ATCC 27853: Tryptic Soy Broth

**Streptococcus pyogenes* ATCC 51878 was grown at 37°C in a tri-gas incubator.

Method for Figure 1.

10 **[0058]** Pre-cultures were diluted to an OD600 of 0.0025 in 3 ml MHII medium supplemented with appropriate concentrations of cannabinoids. At various time points, 100 µl of culture was removed from each tube and serial 10-fold dilutions were spotted onto MHII agar plates (10 µl), which were incubated at 37°C for 24 h, and the colonies were counted (CFU).

15

Method for Tables 1-3. MIC determinations were carried out as described above.

Method for Tables 4-7. Interaction of cannabinoids CBC, CBD and CBG with Terpenes and daptomycin:

20 **[0059]** FICI values was determined in a 96 well checkerboard format using the MIC assay for cannabinoids (compound A), terpenes (compound B), and daptomycin (compound C) alone and in combinations. Terpene stocks were prepared in DMSO and diluted in the growth medium. The fractional inhibitory concentration for each compound was calculated as follows: $FIC_A = (\text{MIC of compound A in the presence of compound B}) / (\text{MIC of compound A alone})$. Similarly, the FICs for compounds B and C were calculated. The FICI was calculated as FIC_A plus FIC_B plus FIC_C .

25 **[0060]** Table 1: Cannabinoids have activity against diverse Gram-positive bacteria but not against Gram-negative bacteria, (*Pseudomonas aeruginosa* ATCC 27853, *Acinetobacter baumannii* ATCC 19606, *E. coli* HB101, data not shown).

30 Sensitivities are expressed as MICs (mg/L).

Table 1	CBD	CBDA	CBG	CBGA	CBC	CBCA
<i>Staphylococcus aureus</i> MRSA	2	16	1	1	4	4
<i>Streptococcus pyogenes</i> ATCC 51878	1	8	1	2	1	0.5-1
<i>Enterococcus faecium</i> 33D3	1-2	16	1-2	16	1-2	4
<i>Enterococcus faecalis</i>	2	16	1	8	2	4
<i>Staphylococcus epidermidis</i> ATCC 14990	2	4	1-2	2	4	2
<i>Staphylococcus epidermidis</i> ATCC 12228	2	4	2	2	4	2
<i>Mycobacterium abscessus</i> ATCC 19977	16	32	2	16	4	4
<i>Mycobacterium tuberculosis</i> H37Rv Media PB	4	4	2	2	4	4
<i>Mycobacterium tuberculosis</i> H37Rv Media 7H9	16	2	2	4	8	2

Table 2: Cannabinoid activity against clinical enterococcal strains (vancomycin sensitive, vancomycin resistant, and resistant to both vancomycin and daptomycin), expressed as MICs (mg/L).

Cannabinoids	33D3	69C6*	58C9 [#]	55A6 [#]
CBD	1	1	1	2
CBDA	16	16	16	16
CBG	1	1	1	1
CBGA	16	8	16	8
CBC	1	1	1	1
CBCA	4	4	4	2
Daptomycin	2	1	8	8

* Vancomycin resistant

[#] Daptomycin resistant (MIC is greater than 4 mg/L)

- 5 Table 3: Cannabinoids potentiate the activity of daptomycin against clinical isolates of *E. faecium*.

	Fold reduction in daptomycin MIC in combination with:		
Isolate	CBD	CBG	CBC
33D3	16	32	128
69C6*	4	4	32
55a6 [#]	16	4	512
58c9 [#]	32	64	8

* indicates that the strain is vancomycin resistant.

[#] Daptomycin resistant strains (MIC is greater than 4 mg/L).

10

Table 4: Synergistic and potentiating interactions of pairwise and triple combinations of Cannabinoids (CBC, CBD, or CBG), Trans-caryophyllene, and Daptomycin inhibit *E. faecium* 33D3 growth.

A. Pairwise interactions of CBC, Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.51	Synergy
CBC		
Daptomycin	0.25-0.75	Potentiation/Synergy
Trans-caryophyllene		
CBC	0.37	Synergy
Trans-caryophyllene		

4B. Pairwise interactions of CBD, Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.56	Likely Synergy
CBD		
Daptomycin	0.25-0.75	Potentiation/Synergy
Trans-caryophyllene		
CBD	0.37	Synergy
Trans-caryophyllene		

5

4C. Pairwise interactions of CBG, Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.53	Synergy
CBG		
Daptomycin	0.25-0.75	Potentiation/Synergy
Trans-caryophyllene		
CBG	0.37-0.5	Synergy
Trans-caryophyllene		

10 4D. Interactions of Triple Combinations of a cannabinoid (CBC, CBD, or CBG), Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.75*	Synergy
CBC, Trans-caryophyllene		
Daptomycin	0.75	Synergy
CBD, Trans-caryophyllene		
Daptomycin	0.81	Synergy
CBG, Trans-caryophyllene		

*For triple combinations, FICI <1.0 represents synergy

Table 5: Maximal fold increases in the activities of individual Cannabinoids (CBC, CBD, CBG), Trans-caryophyllene and Daptomycin in pairwise and triple combinations against *E. faecium* 33D3.

5A. Pairwise interactions of CBC, Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change In MIC
	Alone	In combination	
Daptomycin	4	0.03125	128 ↓
CBC	2	0.5	4 ↓
Daptomycin	4	0.5	8 ↓
Trans-caryophyllene	>16	4	>4 ↓
CBC	2	0.125	16 ↓
Trans-caryophyllene	16	0.25	64 ↓

5B. Pairwise interactions of CBD, Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC
	Alone	In combination	
Daptomycin	4	0.25	16 ↓
CBD	4	1	4 ↓
Daptomycin	4	0.5	8 ↓
Trans-caryophyllene	>16	4	>4 ↓
CBD	2	0.125	16 ↓
Trans-caryophyllene	16	2	8 ↓

5C. Pairwise interactions of CBG, Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC
	Alone	In combination	
Daptomycin	8	0.25	32 ↓
CBG	4	0.125	32 ↓
Daptomycin	4	0.5	8 ↓
Trans-caryophyllene	>16	4	>4 ↓
CBG	2	0.125	16 ↓
Trans-caryophyllene	32	4	8 ↓

5

5D. Interactions of Triple Combinations of a Cannabinoid (CBC, CBD, or CBG), Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC ¹⁰
	Alone	In combination	
Daptomycin	8	4	2 ↓
CBC, Trans-caryophyllene	2, 16	0.25, 2	8 ↓
Daptomycin	8	0.03	256 ↓ 15
CBD, Trans-caryophyllene	2, 16	0.5, 2	4, 8 ↓
Daptomycin	8	2	4 ↓
CBG, Trans-caryophyllene	1, 16	0.25, 1	4, 16 ↓

20 Table 6: Synergistic and potentiating pairwise or triple interactions of cannabinoids (CBC, CBD, CBG), trans-caryophyllene, and daptomycin inhibit *E. faecium* VRE 55A6 growth.

6A. Pairwise interactions of CBC, Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.5	Synergy
CBC		
Daptomycin	0.5-0.625	Synergy/Potentiation
Trans-caryophyllene		
CBC	0.51-0.53	Synergy
Trans-caryophyllene		

6B. Pairwise interactions of CBD, Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.5	Synergy
CBD		
Daptomycin	0.5-0.625	Synergy/Potentiation
Trans-caryophyllene		
CBD	0.5-0.75	Potentiation
Trans-caryophyllene		

5

6C. Pairwise interactions of CBG, Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
--------------	------	-------------

Daptomycin	0.75	Potentiation
CBG		
Daptomycin	0.5-0.625	Synergy/Potentiation
Trans-caryophyllene		
CBG	>1	No interaction
Trans-caryophyllene		

6D. Interactions of Triple Combinations of a Cannabinoid (CBC, CBD, or CBG), Trans-caryophyllene and Daptomycin

Combinations	FICI	Interaction
Daptomycin	0.25-0.56	Synergy
CBC, Trans-caryophyllene		
Daptomycin	0.25-0.44	Synergy
CBD, Trans-caryophyllene		
Daptomycin	0.5-0.69	Synergy
CBG, Trans-caryophyllene		

5 * For triple combinations, FICI <1.0 represents synergy

Table 7: Maximal fold increases in the activities of individual cannabinoids (CBC, CBD, CBG), trans-caryophyllene and daptomycin in pairwise or triple combinations against *E. faecium* VRE 55A6.

7A. Pairwise interactions of CBC, Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC
	Alone	In combination	
Daptomycin	16	0.031	512 ↓
CBC	2	0.25	8 ↓
Daptomycin	16	8	2 ↓
Trans-caryophyllene	>16	2	>8 ↓
CBC	1	0.5	2 ↓
Trans-caryophyllene	>32	1	>32 ↓

7B. Pairwise interactions of CBD, Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC
	Alone	In combination	
Daptomycin	16	1	16 ↓
CBD	4	0.5	8 ↓
Daptomycin	16	8	2 ↓
Trans-caryophyllene	>16	2	>8 ↓
CBD	2	1	2 ↓
Trans-caryophyllene	>32	8	>4 ↓

7C. Pairwise interactions of CBG, Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC
	Alone	In combination	
Daptomycin	16	4	4 ↓
CBG	4	2	2 ↓
Daptomycin	16	8	2 ↓
Trans-caryophyllene	>16	2	>8 ↓
CBG	2	2	none
Trans-caryophyllene	>32	>32	none

7D. Interactions of Triple Combinations of a Cannabinoid (CBC, CBD, or CBG),

5 Trans-caryophyllene and Daptomycin

Combinations	MIC (mg/L)		Max. fold change in MIC
	Alone	In combination	
Daptomycin	>16	0.03	>512 ↓
CBC, Trans-caryophyllene	2, >64	0.25, 2	8, >32 ↓
Daptomycin	>16	2	>8 ↓
CBD, Trans-caryophyllene	4, >64	0.5, 2	8, >32 ↓
Daptomycin	>16	2	>8 ↓
CBG, Trans-caryophyllene	2, >64	0.5, 2	4, > 32 ↓

[0061] The foregoing data illustrate particularly important interactions with certain cannabinoid-daptomycin combinations, evidencing synergy: e.g. Table 6A FICI=0.5 for CBC+Daptomycin; Table 6B FICI = 0.5 for CBD+daptomycin. In addition to the respective relative amounts that gave synergy, this data illustrates that other relative amounts produce surprising and unexpected significant growth inhibition of *E. faecium*: e.g. Table 5A shows a 128-fold reduction in the MIC of daptomycin (MIC reduced to from 4 to 0.03125 mg/L). This effect occurred when CBC was present at 1/2 its MIC (i.e., CBC MIC reduced from 1 to 0.5 mg/L; data not shown). This interaction occurred with each partner in potentiating ratios, relative amounts of 0.5:0.03125 = 16:1 CBC:Daptomycin.

Example 2: Cannabinoid Sensitization to Daptomycin

[0062] As illustrated in **Figure 2**, cannabinoids sensitize antibiotic resistant Enterococcal strains to daptomycin. **Figure 2** reflects data illustrating the effects of daptomycin (Dap), and Dap in combination with CBD, CBG or CBC, on daptomycin resistant *E. faecium* VRE strains 58C9 and 55A6. *E. faecium* strain 55A6 is resistant to daptomycin with a daptomycin MIC=8mg/L. *E. faecium* strains 58C9 and 55A6 were incubated with no cannabinoid (A,B), or 1/2x (0.5mg/L) MIC of CBD (C,D), CBG (E,F) or CBC (G,H) with 1x (4mg/L for 58C9; 8mg/L for 55A6), 1/2x (2mg/L for 58C9; 4mg/L for 55A6), 1/4x (1mg/L for 58C9; 2mg/L for 55A6) or 1/8x (0.5 mg/L for 58C9; 1mg/L for 55A6) MIC of daptomycin. Aliquots were removed at 2, 4, 6, 8 and 24h for CFU enumeration. Data points are the means from three replicates with standard deviations presented as error bars. As illustrated, adding approximately 1/2 MIC of each cannabinoid facilitated killing by daptomycin at 1/4-1/8x the MIC of daptomycin.

[0063] To further illustrate the bactericidal potentiation activity of CBD, CBG and CBC with daptomycin, kill curves were generated with *E. faecium* strain 33D3 (daptomycin sensitive, MIC=1), as illustrated in **Figure 3**. This data is usefully compared to the data in **Figure 2** for *E. faecium* strains 58C9 (daptomycin intermediate resistance MIC=4) and 55A6 (daptomycin resistant, MIC=8). As illustrated, strains were each incubated with 1/8x to 1x MIC of daptomycin (0.25-1mg/L daptomycin for 33D3, 0.5-4mg/L daptomycin for 58C9 and 1-8mg/L

daptomycin for 55A6) and with 0.5x MIC of CBD, CBG or CBC. At 1/2x MIC there was effectively no inhibition of growth by a cannabinoid or daptomycin in all strains. Of note, although daptomycin did inhibit growth at 1x MIC, there was no reduction in CFU. However, 1/2x MIC of CBD, CBG or CBC in combination of 1x-1/8x MIC of
 5 daptomycin significantly inhibited growth of all strains and reduced CFU, thereby demonstrating bactericidal activity (**Figures 2 and 3**). This has particularly important clinical relevance, since daptomycin is generally not used to treat patients infected by strains classified as daptomycin resistant (MIC > 4mg/L). Strains 58C9 and 55A6 are daptomycin intermediate resistant and resistant respectively, but in the presence
 10 of 1/2x MIC of CBD, CBG or CBC, as little as 1mg/L Daptomycin (1/8x MIC) could significantly reduce the CFU at 24h (**Figure 2**).

[0064] This Example further illustrates that a broad range of relative cannabinoid-daptomycin amounts can provide surprising and unexpected results, as evidenced by the kill curves in **Figures 2 and 3**. For example, surprising and clinically
 15 meaningful effects were seen at the following relative cannabinoid-daptomycin amounts: For CBC:Daptomycin 1:1-4 (**Figure 3** 33D3 strain), 1:1-8 (**Figure 2**; 58C9 Strain), and 1:4-16 (**Figure 2** 55A6 Strain); For CBG:Daptomycin 2:1 and 1:1-4 (**Figure 3** 33D3 Strain), 1:1-8 (**Figure 2**; 58C9 Strain), and 1:2-16 (**Figure 2**; 55A6 Strain); and, for CBD:Daptomycin 2:1 and 1:1-4 (**Figure 3** 33D3 Strain), 1:1-8
 20 (**Figure 2**; 58C9), and 1:2-16 (**Figure 2**; 55A6 Strain).

Example 3: CBD and CBG Biofilm Inhibition

[0065] This example illustrates that CBD and CBG are surprisingly effective at inhibiting *E. faecium* biofilm growth. The data in **Figure 4** was generated by growing
 25 biofilms of *E. faecium* strain 33D3 for 48h without cannabinoids, then treating the biofilms with cannabinoids for 72h. The mass of the biofilm was quantitated by crystal violet staining. Viable bacteria in the biofilm were quantitated by scrapping biofilm then counting the viable bacteria. As illustrated, CBD and CBG illustrate a surprising degree of antibiotic activity against the strain 33D3 of *E. faecium*. Of note, CBC was
 30 bactericidal against planktonic Enterococci.

REFERENCES

- [0066]** Abdelaziz, A., (1982) Studies on the antimicrobial activity of cannabinoids. MS thesis, Ohio State University.
- [0067]** André, C. M.; Hausman, J.-F.; Guerriero, G. (2016). "Cannabis sativa: The
5 Plant of the Thousand and One Molecules". *Frontiers in Plant Science*. 7: 19.
- [0068]** Appendino, G., G. Chianese & O. Tagliatela-Scafati, (2011) Cannabinoids: occurrence and medicinal chemistry. *Curr Med Chem* 18: 10854099.
- [0069]** Appendino, G., S. Gibbons, A. Giana, A. Pagani, G. Grassi, M. Stavri, E. Smith & M.M. Rahman, (2008) Antibacterial cannabinoids from *Cannabis sativa*: a
10 structure-activity study. *J Nat Prod* 71: 1427-1430.
- [0070]** Arias, C.A. & B.E. Murray, (2012) The rise of the *Enterococcus*: beyond vancomycin resistance. *Nat Rev Microbiol* 10: 266-278.
- [0071]** Arias, C.A., D. Panesso, D.M. McGrath, X. Qin, M.F. Mojica, C. Miller, L. Diaz, T.T. Tran, S. Rincon, E.M.
- [0072]** Baltz RH (December 2006). "Molecular engineering approaches to peptide, polyketide and other antibiotics". *Nature Biotechnology*. 24 (12): 1533–40.
- [0073]** Barbu, J. Reyes, J.H. Roh, E. Lobos, E. Sodergren, R. Pasqualini, W. Arap, J.P. Quinn, Y. Shamoo, B.E. Murray & G.M. Weinstock, (2011) Genetic basis for in vivo daptomycin resistance in enterococci. *N Engl. J Med* 365: 892-900.
- [0074]** Berenbaum, M. C. 1978. A method for testing for synergy with any number
20 of agents. *J. Infect. Dis.* 137:122-130.
- [0075]** Arthur, M. & P. Courvalin, (1993) Genetics and mechanisms of glycopeptide resistance in enterococci. *Antimicrob Agents Chemother* 37: 1563-1571.
- [0076]** Consroe, P., J. Laguna, J. Allender, S. Snider, L. Stern, R. Sandyk, K. Kennedy & K. Schram, (1991) Controlled clinical trial of cannabidiol in Huntington's disease. *Pharmacol Biochem Behav* 40: 701-708.
- [0077]** Cunha, J.M., E.A. Carlini, A.E. Pereira, O.L. Ramos, C. Pimentel, R. Gagliardi, W.L. Sanvito, N. Lander & R. Mechoulam, (1980) Chronic administration
30 of cannabidiol to healthy volunteers and epileptic patients. *Pharmacology* 21: 175-185.

- [0078]** Eisohly, H.N., C.E. Turner, A.M. Clark & M.A. Eisohly, (1982) Synthesis and antimicrobial activities of certain cannabichromene and cannabigerol related compounds. *J Pharm Sci* 71: 1319-1323.
- [0079]** Galloway-Pena, J.R., S.R. Nallapareddy, C.A. Arias, G.M. Eliopoulos & B.E. Murray, (2009) Analysis of clonality and antibiotic resistance among early clinical isolates of *Enterococcus faecium* in the United States. *J Infect Dis* 200: 1566-1573.
- [0080]** Hidron, A.I., J.R. Edwards, J. Patel, T.C. Horan, D.M. Sievert, D.A. Pollock, S.K. Fridkin, T. National Healthcare Safety Network & F. Participating National Healthcare Safety Network, (2008) NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. *Infect Control Hosp Epidemiol* 29: 996-1011.
- [0081]** Luo X, Reiter MA, d'Espaux L, Wong J, Denby CM, Lechner A, Zhang Y, Grzybowski AT, Harth S, Lin W, Lee H, Yu C, Shin J, Deng K, Benites VT, Wang G, Baidoo EEK, Chen Y, Dev I, Petzold CJ, Keasling JD. 2019. Complete biosynthesis of cannabinoids and their unnatural analogues in yeast. *Nature* 567:123-126
- [0082]** Mechoulam, R. & Y. Gaoni, (1965) Hashish. IV. The isolation and structure of cannabinolic cannabidiolic and cannabigerolic acids. *Tetrahedron* 21: 1223-1229.
- [0083]** Miao V, Coëffet-Le Gal MF, Nguyen K, Brian P, Penn J, Whiting A, Steele J, Kau D, Martin S, Ford R, Gibson T, Bouchard M, Wrigley SK, Baltz RH (March 2006). "Genetic engineering in *Streptomyces roseosporus* to produce hybrid lipopeptide antibiotics". *Chemistry & Biology*. 13 (3): 269–76.
- [0084]** Morales, P., D.P. Hurst & P.H. Reggio, (2017) Molecular Targets of the Phytocannabinoids: A Complex Picture. *Prog Chem Org Nat Prod* 103: 103-131.
- [0085]** Murdoch, D.R., G.R. Corey, B. Hoen, J.M. Miro, V.G. Fowler, Jr., A.S. Bayer, A.W. Karchmer, L. Olaison, P.A. Pappas, P. Moreillon, S.T. Chambers, V.H. Chu, V. Falco, D.J. Holland, P. Jones, J.L. Klein, N.J. Raymond, K.M. Read, M.F. Tripodi, R. Utili, A. Wang, C.W. Woods, C.H. Cabell & I. International Collaboration on Endocarditis-Prospective Cohort Study, (2009) Clinical presentation, etiology, and outcome of infective endocarditis in the 21st century: the International Collaboration on Endocarditis-Prospective Cohort Study. *Arch Intern Med* 169: 463-473.

- [0086]** Najafi K, Ganbarov K, Gholizadeh P, Tanomand A, Rezaee MA, Mahmood SS, Asgharzadeh M, Kafil HS. 2019. Oral cavity infection by *Enterococcus faecalis*: virulence factors and pathogenesis. *Reviews in Medical Microbiology* 29: 000 Publish Ahead of Print.
- 5 **[0087]** Nguyen KT, Kau D, Gu JQ, Brian P, Wrigley SK, Baltz RH, Miao V (September 2006). "A glutamic acid 3-methyltransferase encoded by an accessory gene locus important for daptomycin biosynthesis in *Streptomyces roseosporus*". *Molecular Microbiology*. 61 (5): 1294–307.
- [0088]** Nguyen, K. T., He, X., Alexander, D. C., Li, C., Gu, J. Q., Mascio, C., Van
10 Praagh, A., Mortin, L., Chu, M., Silverman, J. A., Brian, P., & Baltz, R. H. (2010). Genetically engineered lipopeptide antibiotics related to A54145 and daptomycin with improved properties. *Antimicrobial agents and chemotherapy*, 54(4), 1404–1413.
- [0089]** Odds, F.C., Synergy, antagonism, and what the chequerboard puts between them, *Journal of Antimicrobial Chemotherapy*, (2003) 52, 1.
- 15 **[0090]** Paganelli, Fernanda L et al. "Enterococcus faecium biofilm formation: identification of major autolysin AtlAEfm, associated Acm surface localization, and AtlAEfm-independent extracellular DNA Release." *mBio* vol. 4,2 e00154. 16 Apr. 2013, doi:10.1128/mBio.00154-13.
- [0091]** Prematunge, C., C. MacDougall, J. Johnstone, K. Adomako, F. Lam, J.
20 Robertson & G. Garber, (2016) VRE and VSE Bacteremia Outcomes in the Era of Effective VRE Therapy: A Systematic Review and Meta-analysis. *Infect Control Hosp Epidemiol* 37: 26-35.
- [0092]** Russo, E.B., (2011) Taming THC: potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. *Br J Pharmacol* 163: 1344-1364.
- 25 **[0093]** Schleifer, K.H. & R. Kilpperbalz, (1984) Transfer of *Streptococcus-Faecalis* and *Streptococcus-Faecium* to the Genus *Enterococcus* Nom Rev as *Enterococcus-Faecalis* Comb-Nov and *Enterococcus-Faecium* Comb-Nov. *Intl Syst Bacteriol* 34: 31-34.
- [0094]** Steenackers, B.; De Cooman, L.; De Vos, D. (2015). "Chemical
30 transformations of characteristic hop secondary metabolites in relation to beer properties and the brewing process: A review". *Food Chemistry*. 172: 742–756.

- [0095]** Trost and Dogra, (2007) Synthesis of (-)- Δ^9 -trans-Tetrahydrocannabinol - Stereocontrol via Mo-catalyzed Asymmetric Allylic Alkylation Reaction. *Org Lett.* 2007 March 1; 9(5): 861–863.
- [0096]** Turner, C.E. & M.A. Elsohly, (1981) Biological activity of
5 cannabichromene, its homologs and isomers. *J Clin Pharmacol* 21: 2835-2915. Van
Klingeren, B. & M. Ten Ham, (1976) Antibacterial activity of delta9-
tetrahydrocannabinol and cannabidiol. *Antonie Van Leeuwenhoek* 42: 9-12.
- [0097]** Yu, V. L., T. P. Felegie, R. B. Yee, A. W. Pasculle, and F. H. Taylor. 1980.
Synergistic interaction in vitro with use of three antibiotics simultaneously against
10 *Pseudomonas maltophilia*. *J. Infect. Dis.* 142:602-607.
- [0098]** Zhong et al., (2017) Comparative genomic analysis of the genus
Enterococcus. *Microbiological Research*, Volume 196, March 2017, Pages 95-105.

CLAIMS

1. A method of treating a bacterial infection in a subject in need thereof, comprising administering to the subject an effective amount of:
 - 5 a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); and,
a lipopeptide antibiotic that is daptomycin or an analogue thereof;
wherein the cannabinoid and the lipopeptide antibiotic are administered in an
antibiotically effective weight ratio of from 16:1 to 1:16; and,
 - 10 wherein:
 - if the cannabinoid is CBD, then the lipopeptide antibiotic is
administered in an effective amount that is less than 4 mg/kg; and/or,
 - if the cannabinoid is CBD, then the bacterial infection comprises
infection by an infectious organism having a daptomycin MIC of 4 µg/mL or
15 greater; and/or,
 - if the cannabinoid is CBD, then the bacterial infection comprises
infection by an infectious organism for which results from an assay of
bacterial growth indicate that daptomycin produces an inhibitory and/or
bactericidal effect at concentrations of less than 4 µg/mL when administered
20 with CBD in an amount that is less than the MIC of CBD.
2. The method of claim 1, wherein the bacterial infection comprises infection by an infectious organism having a daptomycin MIC of 4 µg/mL or greater.
- 25 3. The method of claim 1 or 2, wherein the bacterial infection comprises infection by an *Enterococcus faecium* or an *Enterococcus faecalis*.
4. The method of any one of claims 1 to 3, further comprising administering to the subject an effective amount of a sesquiterpene that is one or both of α-
30 humulene and/or β-caryophyllene.
5. An antibiotic formulation, comprising:
a cannabinoid that is one or more of cannabichromene (CBC) and/or

cannabigerol (CBG); and,

a lipopeptide antibiotic that is daptomycin or an analogue thereof;
wherein the cannabinoid and the lipopeptide antibiotic are present in an
antibiotically effective weight ratio of from 16:1 to 1:16.

5

6. The formulation of claim 5, wherein the cannabinoid is present in an amount
that reduces the minimum inhibitory concentration (MIC) of the lipopeptide antibiotic
in an antibiotic assay.

10 7. The formulation of claim 6, wherein the cannabinoid reduces the MIC of the
lipopeptide antibiotic in the assay when the cannabinoid is present in an amount
that is less than the MIC of the cannabinoid.

8. The formulation of any one of claims 5 to 7, wherein the formulation further
15 comprises a sesquiterpene.

9. The formulation of claim 8, wherein the sesquiterpene is one or both of α -
humulene and/or β -caryophyllene.

20 10. The formulation of any one of claims 1 to 9, wherein the assay is an
Enterococcal assay that assesses the inhibition of growth and/or reproduction of an
Enterococcus faecium or an *Enterococcus faecalis*.

11. A formulation, comprising at least two antibiotically active ingredients
25 selected from:

a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol
(CBD) and/or cannabigerol (CBG); and/or,

a sesquiterpene that is one or both of α -humulene and/or β -caryophyllene;
and/or,

30 a lipopeptide antibiotic that is daptomycin or an analogue thereof;
wherein the antibiotically active ingredients are present in synergistically
effective relative amounts, wherein an effective amount of the formulation is
synergistically effective in an assay to inhibit growth and/or reproduction of an

Enterococcus faecium or an *Enterococcus faecalis*, and wherein if the formulation comprises CBD and daptomycin, it further comprises at least one additional antibiotically active ingredient.

5 12. The formulation of claim 11, wherein there are two antibiotically active ingredients, and the two antibiotically active ingredients are the cannabinoid and the sesquiterpene.

10 13. The formulation of claim 11, wherein there are two antibiotically active ingredients, and the two antibiotically active ingredients are the cannabinoid and the lipopeptide antibiotic.

15 14. The formulation of claim 11, comprising the cannabinoid, the sesquiterpene and the lipopeptide antibiotic.

15 15. The formulation of claim 11, wherein there are two antibiotically active ingredients, and the two antibiotically active ingredients are the sesquiterpene and the lipopeptide antibiotic.

20 16. The formulation of any one of claims 11 to 14, wherein the cannabinoid is one of CBC, CBD or CBG.

25 17. The formulation of any one of claims 11 to 14, wherein the cannabinoid is two of CBC, CBD and CBG.

25 18. The formulation of any one of claims 11 to 14, wherein the cannabinoid comprises CBC, CBD and CBG.

30 19. The formulation of any one of claims 11 to 18, wherein the sesquiterpene, if present, is one of α -humulene or β -caryophyllene.

20. The formulation of any one of claims 11 to 18, wherein the sesquiterpene, if

present, comprises α -humulene and β -caryophyllene.

21. The formulation of any one of claims 11 to 20, wherein the lipopeptide antibiotic, if present, is daptomycin.

5

22. The formulation of any one of claims 11 to 21, wherein the sesquiterpene, when present, is present in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the cannabinoid in the assay.

10

23. The formulation of any one of claims 11 to 22, wherein the cannabinoid, when present, is present in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the sesquiterpene in the assay.

15

24. The formulation of any one of claims 11 to 23, wherein the sesquiterpene and/or the cannabinoid, when present, is present in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the lipopeptide antibiotic in the assay.

20

25. The formulation of any one of claims 11 to 24, wherein the sesquiterpene and the cannabinoid, when present, are present in a molar ratio that is ≥ 50 .

25

26. The formulation of any one of claims 11 to 25, further comprising a pharmaceutically acceptable excipient, and wherein the antibiotically active ingredients are dissolved, dispersed, mixed or suspended in the formulation.

25

27. The formulation of any one of claims 11 to 26, wherein the cannabinoid, when present, is present at 0.1 - 100 mg/L.

30

28. The formulation of any one of claims 11 to 27, wherein the sesquiterpene, when present, is present at 0.1 - 500 mg/L.

29. The formulation of any one of claims 11 to 28, wherein the cannabinoid and/or sesquiterpene, when present, are derived from a plant.

30. The formulation of claim 29, wherein the plant is a *Cannabis sativa* or *Cannabis indica* plant.
31. The formulation of claim 11, wherein there are two antibioticly active ingredients, and the two antibioticly active ingredients are cannabinoids.
32. The formulation of any one of claims 11 to 31, wherein the formulation does not comprise any alternative cannabinoids, terpenes or lipopeptide antibiotics.
33. The formulation of any one of claims 21 to 31, wherein the formulation consists essentially of two or more of the cannabinoid, the sesquiterpene or the lipopeptide antibiotic.
34. Use of the formulation of any one of claims 5 to 33, to formulate a medicament.
35. The use according to claim 34, wherein the medicament is for use in treating an enterococcal infection in a subject in need thereof.
36. Use of the formulation of any one of claims 5 to 33, to treat an enterococcal infection in a subject in need thereof.
37. The use according to claim 35 or 36, wherein the enterococcal infection is an *Enterococcus faecium* or an *Enterococcus faecalis* infection.
38. The use according to any one of claims 35 to 37, wherein the enterococcal infection is an oral infection.
39. The use according to claim 38, wherein the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary infection, dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion.

40. The use according to any one of claims 35 to 39, wherein the enterococcal infection is an antibiotic resistant enterococcal infection.
41. The use according to claim 40, wherein the antibiotic resistant enterococcal infection is a vancomycin and/or daptomycin resistant enterococcal infection.
42. The use according to any one of claims 34 to 41, wherein the formulation is for use in an amount of that delivers an effective dose of the cannabinoid, when present, of from 1 to 5,000 mg per day, and/or an effective dose of the sesquiterpene, when present, of from 1 to 10,000 mg per day.
43. A method of treating an enterococcal infection in a subject in need thereof, comprising administering to the subject an effective amount of the formulation of any one of claims 5 to 10.
44. A method of treating an enterococcal infection in a subject in need thereof, comprising administering to the subject an effective amount of the formulation of any one of claims 11 to 33.
45. The method of claim 44, wherein the formulation comprises two antibioticly active ingredients, wherein the two antibioticly active ingredients are the cannabinoid and the sesquiterpene, further comprising treating the subject with an effective amount of one or more antibiotics, optionally wherein the antibiotic is daptomycin.
46. The method of any one of claims 43 to 45, comprising administering the cannabinoid in an effective amount of 1-5,000 mg/day.
47. The method of any one of claims 44 to 46, comprising administering the sesquiterpene in an effective amount of 1-10,000 mg/day.
48. A method of treating an enterococcal infection in a subject in need thereof, comprising administering to the subject an effective amount of the formulation of

claim 9 or 10, comprising administering the sesquiterpene in an effective amount of 1-10,000 mg/day.

49. The method of any one of claims 43 to 48, wherein the subject is a mammal.

50. The method of claim 49, wherein the mammal is a human.

51. The formulation of any one of claims 5 to 33, for use to treat an enterococcal infection in a subject in need thereof.

52. The formulation of claim 51, wherein the enterococcal infection is an *Enterococcus faecium* or an *Enterococcus faecalis* infection.

53. The formulation of claim 51 or 52, wherein the enterococcal infection is an oral infection.

54. The formulation of claim 53, wherein the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary infection, dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion.

55. The formulation of any one of claims 51 to 54, wherein the enterococcal infection is an antibiotic resistant enterococcal infection.

56. The formulation of claim 55, wherein the antibiotic resistant enterococcal infection is a vancomycin and/or daptomycin resistant enterococcal infection.

57. The formulation of any one of claims 51 to 56, wherein the formulation is for use in an amount of that delivers an effective dose of the cannabinoid, when present, of from 1 to 5,000 mg per day, and/or an effective dose of the sesquiterpene, when present, of from 1 to 10,000 mg per day.

58. A method of treating a microbial infection in a subject in need thereof, comprising administering to the subject, sequentially or in combination, an effective amount of at least two antibiotically active compounds selected from:
- a cannabinoid that is one or more of cannabichromene (CBC), cannabidiol (CBD) and/or cannabigerol (CBG); and/or,
 - a sesquiterpene that is one or both of α -humulene and/or β -caryophyllene; and/or,
 - a lipopeptide antibiotic that is daptomycin or an analogue thereof;
- wherein the antibiotically active compounds are administered in synergistically effective relative amounts effective to treat the microbial infection, and,
- wherein if the formulation comprises CBD and daptomycin, it further comprises at least one additional antibiotically active ingredient.
59. The method of claim 58, wherein the synergistically effective relative amounts are synergistically effective to inhibit growth and/or reproduction of an *Enterococcus faecium* or an *Enterococcus faecalis* in an assay.
60. The method of claim 58 or 59, wherein the cannabinoid and the sesquiterpene are co-administered, or the sesquiterpene and the lipopeptide antibiotic are co-administered, or the cannabinoid and the lipopeptide antibiotic are co-administered, or the cannabinoid the sesquiterpene and the lipopeptide antibiotic are co-administered.
61. The method of claim 58 or 59, wherein the cannabinoid and the sesquiterpene, or the sesquiterpene and the lipopeptide antibiotic, or the cannabinoid and the lipopeptide antibiotic, or the cannabinoid the sesquiterpene and the lipopeptide antibiotic, are administered sequentially, in any order.
62. The method of any one of claims 58 to 61, further comprising further treating the subject with the lipopeptide antibiotic alone.
63. The method of any one of claims 58 to 62, wherein the cannabinoid, if

administered, is one of CBC, CBD or CBG.

64. The method of any one of claims 58 to 62, wherein the cannabinoid, if administered, is two of CBC, CBD and CBG.

5

65. The method of any one of claims 58 to 62, wherein the cannabinoid, if administered, comprises CBC, CBD and CBG.

66. The method of any one of claims 58 to 65, wherein the sesquiterpene, if administered, is one of α -humulene or β -caryophyllene.

10

67. The method of any one of claims 58 to 66, wherein the sesquiterpene, if administered, comprises α -humulene and β -caryophyllene.

68. The method of any one of claims 58 to 67, wherein the lipopeptide antibiotic, if administered, is daptomycin.

15

69. The method of any one of claims 58 to 68, wherein the sesquiterpene, if administered, is administered in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the cannabinoid when administered.

20

70. The method of any one of claims 58 to 69, wherein the cannabinoid, if administered, is administered in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the sesquiterpene when administered.

25

71. The method of any one of claims 58 to 70, wherein the sesquiterpene and/or the cannabinoid, when administered, is administered in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the lipopeptide antibiotic when administered.

30

72. The method of any one of claims 58 to 71, wherein the microbial infection comprises a gram positive bacterial infection or an enterococcal infection.

73. The method of claim 72, wherein the enterococcal infection comprises an *Enterococcus faecium* or an *Enterococcus faecalis* infection.
- 5 74. The method of claim 72 or 73, wherein the enterococcal infection is an oral infection.
75. The method of claim 74, wherein the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary
10 infection, dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion.
76. The method of any one of claims 58 to 75, wherein the microbial infection is an antibiotic resistant infection.
- 15 77. The method of claim 76, wherein the antibiotic resistant infection is a vancomycin and/or daptomycin resistant microbial infection.
78. The method of any one of claims 1 to 4, wherein the cannabinoid and the
20 lipopeptide antibiotic are administered in synergistically effective relative amounts effective to treat the bacterial infection.
79. The method of claim 78, wherein the synergistically effective relative amounts are synergistically effective to inhibit growth and/or reproduction of an
25 *Enterococcus faecium* or an *Enterococcus faecalis* in an assay.
- 80 The method of any one of claims 79, wherein the cannabinoid is administered in an amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the lipopeptide antibiotic in the assay.
- 30 81. The method of any one of claims 1-4 or 78-80, wherein the cannabinoid and the lipopeptide antibiotic are co-administered.

82. The method of claim 1-4 or 78-80, wherein the cannabinoid and the lipopeptide antibiotic are administered sequentially, in any order.
83. The method of any one of claims 1-4 or 78-82, further comprising further
5 treating the subject with the lipopeptide antibiotic alone.
84. The method of any one of claims 1-4 or 78-83, wherein the cannabinoid is one of CBC, CBD or CBG.
- 10 85. The method of any one of claims 1-4 or 78-83, wherein the cannabinoid is two of CBC, CBD and CBG.
86. The method of any one of claims 1-4 or 78-83, wherein the cannabinoid comprises CBC, CBD and CBG.
15
87. The method of any one of claims 1-4 or 78-86, wherein the lipopeptide antibiotic is daptomycin.
88. The method of any one of claims 1-4 or 78-87, wherein the cannabinoid is
20 administered in a relative amount that provides at least a 2 to 128 fold decrease in minimum inhibitory concentration (MIC) of the lipopeptide antibiotic.
89. The method of any one of claims 1-4 or 78-88, wherein the bacterial infection is gram positive bacterial infection or an enterococcal infection.
25
90. The method of claim 89, wherein the enterococcal infection is an *Enterococcus faecium* or an *Enterococcus faecalis* infection.
91. The method of claim 89 or 90, wherein the enterococcal infection is an oral
30 infection.
92. The method of claim 91, wherein the oral infection is a marginal periodontitis, a root canal infection, a primary endodontic infection, a persistent or secondary

infection, dental caries, peri-implantitis, periradicular abscess or an oral mucosal lesion.

93. The method of any one of claims 1-4 or 78-92, wherein the bacterial infection
5 is an antibiotic resistant infection.

94. The method of claim 93, wherein the antibiotic resistant infection is a vancomycin and/or daptomycin resistant bacterial infection.

10 95. The method of any one of claims 1-4 or 78-94, comprising administration of an effective dose of the cannabinoid of from 1 to 5,000 mg per day.

96. Use of CBD and/or CBG to inhibit the growth of a biofilm, wherein the biofilm comprises an *Enterococcus faecium* or an *Enterococcus faecalis*.

15

97. A method of inhibiting the growth of a biofilm comprising an *Enterococcus faecium* or an *Enterococcus faecalis*, comprising exposing the biofilm to an effective amount of CBD and/or CBG.

20 98. An invasive medical device comprising an impregnated concentration of CBD and/or CBG, wherein the impregnated concentration of CBD and/or CBG is releasable from the device in vivo at a concentration that is effective to inhibit growth of a biofilm on the device, wherein the biofilm comprises an *Enterococcus faecium* or an *Enterococcus faecalis*.

25

Figure 1




Figure 2




Figure 3





Figure 4



INTERNATIONAL SEARCH REPORT

International application No.

PCT/CA2020/050613

A. CLASSIFICATION OF SUBJECT MATTER

IPC: **A61K 38/15** (2006.01), **A61K 31/015** (2006.01), **A61K 31/05** (2006.01), **A61K 31/352** (2006.01),
A61K 36/185 (2006.01), **A61M 31/00** (2006.01) (more IPCs on the last page)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
 Keywords searched across all IPCs.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database(s) consulted during the international search (name of database(s) and, where practicable, search terms used)
 PubMed, Questel Orbit, Google, Canadian Patent Database: cannabinoid, daptomycin, enterococcus, faecalis, faecium, humulene, caryophyllene, sesquiterpene, antimicrobial, antibacterial.

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO2018/234301 (KLITGAARD JK et al.) 27 December 2018 (27-12-2018) (pages 2, 9, 11 figures 1, 4 examples 1, 2, 4)	1 – 3, 10, 11, 16, 21, 26, 27, 34 – 41, 43, 44, 49 – 56, 58, 59, 63, 68 – 84, 87 – 95
P,X	WO2020/000024 (CALLAHAN M et al.) 2 January 2020 (02-01-2020) (pages 7 – 9, figures 15 – 17, examples 1 - 8)	96 – 98
P,X	WO2020/051284 (MURPHY B et al.) 12 March 2020 (12-03-2020) (example 1)	96 – 98

☐ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* “A” “D” “E” “L” “O” “P”	Special categories of cited documents: document defining the general state of the art which is not considered to be of particular relevance document cited by the applicant in the international application earlier application or patent but published on or after the international filing date document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) document referring to an oral disclosure, use, exhibition or other means document published prior to the international filing date but later than the priority date claimed	“T” “X” “Y” “&”	later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family
---	---	--------------------------	--

Date of the actual completion of the international search
 05 August 2020 (05-08-2020)

Date of mailing of the international search report
 05 August 2020 (05-08-2020)

Name and mailing address of the ISA/CA
 Canadian Intellectual Property Office
 Place du Portage I, C114 - 1st Floor, Box PCT
 50 Victoria Street
 Gatineau, Quebec K1A 0C9
 Facsimile No.: 819-953-2476

Authorized officer

Antonio Candeliere (819) 639-7769

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No.

PCT/CA2020/050613

Patent Document Cited in Search Report	Publication Date	Patent Family Member(s)	Publication Date
WO2018234301A1	27 December 2018 (27-12-2018)	CA3067542A1 EP3641753A1 US2020146999A1	27 December 2018 (27-12-2018) 29 April 2020 (29-04-2020) 14 May 2020 (14-05-2020)
WO2020000024A1	02 January 2020 (02-01-2020)	None	
WO2020051284A1	12 March 2020 (12-03-2020)	None	

A61P 1/02 (2006.01), *A61P 31/04* (2006.01), *C07C 13/271* (2006.01), *C07C 13/32* (2006.01),
C07C 39/19 (2006.01), *C07C 39/23* (2006.01), *C07D 311/58* (2006.01), *C07K 7/08* (2006.01)